Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Pelthos Therapeutics Inc.AMEX: PTHS
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities remains negative
Q1 FY2026 other current liabilities was $15.3M, compared with $0 a year earlier. Over 3 fiscal years it compounded at +358.6% a year.
Context
- Other current liabilities amounted to 10.5% of total assets at the end of Q1 FY2026, up 10.5 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 21.41M USD
- Year-over-year change
- —
- 3-year CAGR
- +358.6%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.41M | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 645.95K | +191.1% |
| FY2022 | 2022-12-31 | 221.88K | — |
Other Current Liabilities vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's Mar 2026 other current liabilities of $15.3M is the highest of the 4 companies compared; the peer median is $251K.
- Other current liabilities amounts to 10.5% of total assets for PTHS, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $15.3M | — | +358.6% | 10.5% | |
| Dec 2025 | $1.89M | +1229.6% | — | 0.1% | |
| Mar 2026 | $251K | +1155.0% | -14.1% | 0.8% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding PTHS) | $251K | +1192.3% | -14.1% | 0.1% | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.